20
Views
8
CrossRef citations to date
0
Altmetric
CASE REPORT

Use of infliximab in a patient with pyoderma gangrenosum and rheumatoid arthritis

, , , , , , & show all
Pages 598-601 | Received 10 May 2010, Accepted 25 Jun 2010, Published online: 02 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings & Alex G. Ortega-Loayza. (2019) Biologic and small-molecule medications in the management of pyoderma gangrenosum. Journal of Dermatological Treatment 30:3, pages 264-276.
Read now
Steve R. Feldman, Frank A. Lacy & William W. Huang. (2018) The safety of treatments used in pyoderma gangrenosum. Expert Opinion on Drug Safety 17:1, pages 55-61.
Read now

Articles from other publishers (6)

Hakim Ben Abdallah, Karsten Fogh & Rikke Bech. (2019) Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review. International Wound Journal 16:2, pages 511-521.
Crossref
Afsaneh Alavi, Lars E. French, Mark D. Davis, Alain Brassard & Robert S. Kirsner. (2017) Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. American Journal of Clinical Dermatology 18:3, pages 355-372.
Crossref
Amira Elbendary & Roselyn Kellen. (2018) Off-Label uses of Biologic Agents Approved for Psoriasis and Psoriatic Arthritis for Dermatological Conditions: Part I. Journal of Psoriasis and Psoriatic Arthritis 2:1, pages 31-37.
Crossref
E.M. DeFilippis, S.R. Feldman & W.W. Huang. (2015) The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. British Journal of Dermatology 172:6, pages 1487-1497.
Crossref
Andrew Gassman, Sammy Sinno, Ross Milner & Richard Gamelli. (2011) Pyoderma gangrenosum: a new complication after groin exposure for attempted endovascular aortic stent-graft placement. Vascular 20:3, pages 170-173.
Crossref
Clio Dessinioti, Alexander J. Stratigos, Andreas Katsambas & Christina Antoniou. (2011) Anti‐tumor necrosis factor‐α therapies for immune‐mediated and inflammatory skin diseases. Drug Development Research 72:7, pages 615-622.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.